Construction and evaluation of a chimeric pseudoinfectious virus vaccine to prevent Japanese encephalitis

Tomohiro Ishikawa, Douglas G. Widman, Nigel Bourne, Eiji Konishi, Peter W. Mason

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Multiple vaccines exist to control Japanese encephalitis (JE), but all suffer from problems. We have developed a new type of flavivirus vaccine, a pseudoinfectious virus (RepliVAX WN) that prevents West Nile virus (WNV)-induced disease. Here, we describe production of a chimeric RepliVAX (RepliVAX JE) that expresses the JE virus (JEV) prM and E proteins. Our prototype RepliVAX JE replicated poorly in cells, but blind passage produced a better-growing derivative, and analyses of this derivative allowed us to engineer a second-generation RepliVAX (RepliVAX JE.2) that grew to high titers. RepliVAX JE.2 elicited neutralizing antibodies in both mice and hamsters and provided 100% protection from a lethal challenge with JEV or WNV, respectively. These results demonstrate the utility our RepliVAX platform for producing a JE vaccine.

Original languageEnglish (US)
Pages (from-to)2772-2781
Number of pages10
JournalVaccine
Volume26
Issue number22
DOIs
StatePublished - May 23 2008

Fingerprint

Japanese Encephalitis
encephalitis
West Nile virus
Vaccines
vaccines
Viruses
Japanese encephalitis virus
viruses
Japanese Encephalitis Virus
Japanese Encephalitis Vaccines
Flavivirus
Virus Diseases
Neutralizing Antibodies
Cricetinae
neutralizing antibodies
hamsters
engineers
prototypes
mice
Proteins

Keywords

  • Chimera
  • Encephalitis virus
  • Japanese
  • Subviral particle

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Construction and evaluation of a chimeric pseudoinfectious virus vaccine to prevent Japanese encephalitis. / Ishikawa, Tomohiro; Widman, Douglas G.; Bourne, Nigel; Konishi, Eiji; Mason, Peter W.

In: Vaccine, Vol. 26, No. 22, 23.05.2008, p. 2772-2781.

Research output: Contribution to journalArticle

Ishikawa, Tomohiro ; Widman, Douglas G. ; Bourne, Nigel ; Konishi, Eiji ; Mason, Peter W. / Construction and evaluation of a chimeric pseudoinfectious virus vaccine to prevent Japanese encephalitis. In: Vaccine. 2008 ; Vol. 26, No. 22. pp. 2772-2781.
@article{6fa3d1c4d536454e928577d1865a3b3f,
title = "Construction and evaluation of a chimeric pseudoinfectious virus vaccine to prevent Japanese encephalitis",
abstract = "Multiple vaccines exist to control Japanese encephalitis (JE), but all suffer from problems. We have developed a new type of flavivirus vaccine, a pseudoinfectious virus (RepliVAX WN) that prevents West Nile virus (WNV)-induced disease. Here, we describe production of a chimeric RepliVAX (RepliVAX JE) that expresses the JE virus (JEV) prM and E proteins. Our prototype RepliVAX JE replicated poorly in cells, but blind passage produced a better-growing derivative, and analyses of this derivative allowed us to engineer a second-generation RepliVAX (RepliVAX JE.2) that grew to high titers. RepliVAX JE.2 elicited neutralizing antibodies in both mice and hamsters and provided 100{\%} protection from a lethal challenge with JEV or WNV, respectively. These results demonstrate the utility our RepliVAX platform for producing a JE vaccine.",
keywords = "Chimera, Encephalitis virus, Japanese, Subviral particle",
author = "Tomohiro Ishikawa and Widman, {Douglas G.} and Nigel Bourne and Eiji Konishi and Mason, {Peter W.}",
year = "2008",
month = "5",
day = "23",
doi = "10.1016/j.vaccine.2008.03.010",
language = "English (US)",
volume = "26",
pages = "2772--2781",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "22",

}

TY - JOUR

T1 - Construction and evaluation of a chimeric pseudoinfectious virus vaccine to prevent Japanese encephalitis

AU - Ishikawa, Tomohiro

AU - Widman, Douglas G.

AU - Bourne, Nigel

AU - Konishi, Eiji

AU - Mason, Peter W.

PY - 2008/5/23

Y1 - 2008/5/23

N2 - Multiple vaccines exist to control Japanese encephalitis (JE), but all suffer from problems. We have developed a new type of flavivirus vaccine, a pseudoinfectious virus (RepliVAX WN) that prevents West Nile virus (WNV)-induced disease. Here, we describe production of a chimeric RepliVAX (RepliVAX JE) that expresses the JE virus (JEV) prM and E proteins. Our prototype RepliVAX JE replicated poorly in cells, but blind passage produced a better-growing derivative, and analyses of this derivative allowed us to engineer a second-generation RepliVAX (RepliVAX JE.2) that grew to high titers. RepliVAX JE.2 elicited neutralizing antibodies in both mice and hamsters and provided 100% protection from a lethal challenge with JEV or WNV, respectively. These results demonstrate the utility our RepliVAX platform for producing a JE vaccine.

AB - Multiple vaccines exist to control Japanese encephalitis (JE), but all suffer from problems. We have developed a new type of flavivirus vaccine, a pseudoinfectious virus (RepliVAX WN) that prevents West Nile virus (WNV)-induced disease. Here, we describe production of a chimeric RepliVAX (RepliVAX JE) that expresses the JE virus (JEV) prM and E proteins. Our prototype RepliVAX JE replicated poorly in cells, but blind passage produced a better-growing derivative, and analyses of this derivative allowed us to engineer a second-generation RepliVAX (RepliVAX JE.2) that grew to high titers. RepliVAX JE.2 elicited neutralizing antibodies in both mice and hamsters and provided 100% protection from a lethal challenge with JEV or WNV, respectively. These results demonstrate the utility our RepliVAX platform for producing a JE vaccine.

KW - Chimera

KW - Encephalitis virus

KW - Japanese

KW - Subviral particle

UR - http://www.scopus.com/inward/record.url?scp=43049180289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43049180289&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2008.03.010

DO - 10.1016/j.vaccine.2008.03.010

M3 - Article

C2 - 18433947

AN - SCOPUS:43049180289

VL - 26

SP - 2772

EP - 2781

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 22

ER -